Acura Pharmaceuticals, Inc. · OTC:ACUR

Acura Pharmaceuticals — Roth Capital Conference March 2014

27 slides from Acura Pharmaceuticals's conference presentation, Mar 10, 2014

  1. Slide 1: Roth Capital – March, 2014

    Roth Capital – March, 2014 Non - Confidential Copyright © 2013 Acura Pharmaceuticals. All rights reserved.

  2. Slide 2: Caution Regarding Forward Looking Statements

    Caution Regarding Forward Looking Statements Certain statements in this presentation constitute "forward - looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 . Such forward - looking statements involve known and unknown risks, uncertainties and other facto

  3. Slide 3: Abuse Deterrent Specialty Pharmaceutical Company

    Abuse Deterrent Specialty Pharmaceutical Company • FDA approved technology • 1 st Aversion® opioid product launched by Pfizer Feb. 2012 • Follow - on products in development • Aversion® (Tamper Resistant) Technology • Impede® (Meth Resistant) Technology • Nexafed ® commercially available December 20

  4. Slide 4: Product Portfolio Summary

    Product Portfolio Summary • Broad pipeline of product candidates • Two proprietary technologies: Aversion® and Impede® Product Area Technology Licensee Status Oxycodone HCL, USP CII Opioid Aversion Pfizer Marketed in the U.S. Hydrocodone/APAP Opioid Aversion IND Active (Jan. 2013) 6 Additional Opioi

  5. Slide 5: Aversion Technology

    Aversion ® Technology Proprietary mixture of inactive ingredients Aversive ingredients intended to deter snorting Physical/chemical properties intended to deter injection 5

  6. Slide 6: Physician Perception of Opioid Abuse

    Physician Perception of Opioid Abuse Source: Company Research, 400 Primary Care, Surgeon, Pain Specialists & Emergency Room Physicians, December 2011 • Snorting and Injecting are the methods with the highest concern for serious adverse health consequences with immediate release opioids 6

  7. Slide 7: Abuse of Opioids is Prevalent

    7 • 37 million people in the United States have used Rx opioids non - medically in their lifetime • Immediate Release (IR) opioids are more frequently abused than Extended Release (ER) opioids Abuse of Opioids is Prevalent Source: SAMHSA, Office of Applied Studies, 2012 National Survey on Drug Use a

  8. Slide 8: Aversion IR Product Markets

    Aversion® IR Product Markets Hydrocodone/ Acetaminophen Source: IMS NPA, MAT Dec. 2013 • 238 million dispensed prescriptions in 2013 • $2.6 billion in sales (mostly generic prices) 8 Oxycodone Oxycodone/ Acetaminophen

  9. Slide 9: Aversion Opioid Product Portfolio

    9 Aversion® Opioid Product Portfolio • Focus on rapid development of Hydrocodone/APAP • Demonstrated application to multiple opioid formulations • All are immediate - release tablets Product Area Technology Licensee Status Oxycodone HCL, USP CII Opioid Aversion Pfizer Marketed in the U.S. Hydrocodon

  10. Slide 10: Aversion Oxycodone HCl Tablets CII

    • Marketed By: Pfizer Inc. • Brand Name: Oxecta ® • FDA Approval: June 17, 2011 (February 2, 2012 1 st commercial sale) • Direct Market Size: 16.7 million annual IR oxycodone Rx’s +3.2% growth versus 2012 ~100 Tabs per Rx • Royalties: 5% to 25% based on level of sales achieved Aversion® Oxycodone HC

  11. Slide 11: Hydrocodone/APAP Development Program

    11 Hydrocodone/APAP Development Program • IND active Jan. 2013 • Three In Vitro Laboratory Studies • Syringing Study (Complete) • Extraction for Injection Study (Complete) • Particle Size Study (Complete) • Four Clinical Studies with 124 subjects in aggregate • 301 – Nasal Abuse Liability Study (n=4

  12. Slide 12: Hydrocodone Acetaminophen Aversion Bioequivalence

    12 Hydrocodone Acetaminophen Aversion® Hydrocodone/APAP Bioequivalent to Norco® (hydrocodone bitartrate /APAP) Single, fasted 10/325mg dose (n=47)

  13. Slide 13: Nasal Snorting Study Design

    Study AP - ADF - 301 (Nasal Snorting) • 40 completers of recreational drug abusers • Randomized, cross - over design • Blinded as to volume, particle size, and visible differences • 5 - arm study: placebo, 2 positive - controls, 2 test articles • Phases: • Drug discrimination/Dose titration • Volume

  14. Slide 14: Nasal Snorting Study Results

    14 Study AP - ADF - 301 (Nasal Snorting) Results Endpoint Aversion Active Control Placebo Drug Liking ( Emax ) 72.1 75.6 p=.22 54.5 p<.00001 Drug Dislike ( Emin ) 40.2 50.4 p=.0042 48.8 p=.00003 Time to Emax ( hrs ) 1.6 0.9 1.1 Take Drug Again 45.1 71.0 p<.00001 42.2 p=.36 • Results consistent with

  15. Slide 15: The Revolution Takes Shape

    15 …The Revolution Takes Shape “Scott Co. sees drop in meth labs with new strategy” - WBIR Knoxville, TN NBC Affiliate

  16. Slide 16: Nexafed is the next generation pseudoephedrine

    16 The next generation pseudoephedrine hydrochloride » maximum strength » non - drowsy » non - prescription » effective nasal and sinus congestion relief » with methamphetamine resistant Impede® technology Nexafed® is:

  17. Slide 17: Nexafed - A Unique Selling Proposition

    17 The only meth - resistant pseudoephedrine product that meets FDA standards demonstrating therapeutic equivalence to the products consumers currently use, such as Sudafed® Sudafed is a registered trademark and product of Johnson & Johnson Nexafed® - A Unique Selling Proposition

  18. Slide 18: Nexafed - Strategy

    18 » Establish Nexafed as the new standard of care at the local pharmacy level ▪ Drive consumer purchases via pharmacy recommendations. » Generate public awareness through media outreach ▪ Draw attention to the meth problem ▪ Establish Nexafed as part of the solution » Attract chain retail attention

  19. Slide 19: Nexafed - Retail Track Record

    19 » 8,300 pharmacies stock and sell Nexafed ® ▪ 12% of the estimated 65,000 retail outlets Nexafed® - Retail Track Record Stocking Reordering Kerr Kroger Fruth Publix Bartells Rite Aid Kroger

  20. Slide 20: Nexafed - A New Standard of Care

    Fruth , Rite Aid and many Independent Pharmacies are leading the charge in addressing meth » Many have replaced all single ingredient pseudoephedrine products with Nexafed ®, exclusively. » Rite Aid replaced all single ingredient pseudoephedrine products in West Virginia with Nexafed ®, rolling out

  21. Slide 21: Nexafed - Success is Contagious

    21 Nexafed® – Success is Contagious » Legislative ▪ West Virginia legislation considering requiring all pseudoephedrine products to require a prescription; with exemption for meth - resistant products ▪ Many approaches being discussed in many states » Media ▪ Investigative reports on the impact of m

  22. Slide 22: Nexafed - Market Opportunities

    22 Nexafed® – Market Opportunities 30mg Market Estimate* 372M Tablets 15.5M Boxes of 24 ~20 Boxes per outlet per month Nexafed ® Avg. Boxes per Store Per Month** Oct - Dec 2013 * 2009 AC Nielsen ** Based on store wholesale purchases 2009 Branded Product Retail Sales in Millions* Claritin - D*** Muci

  23. Slide 23: Nexafed - 2014 Plans

    23 » Continue to raise awareness among pharmacists, pharmacies, consumers, law enforcement, and legislators via public relations, advertising and social media » Build the franchise ▪ Nexafed ® Line Extension #1 – expected launch 2 nd half 2014 ▪ Nexafed ® Line Extension #2 – In development ▪ Improve

  24. Slide 24: Intellectual Property and Financial Information

    Intellectual Property and Financial Information 24

  25. Slide 25: Intellectual Property Position

    • Aversion® Technology patents expire in 2023 to 2025 • 6 U.S. patents issued covering compositions of opioids and certain other abused drugs with functional inactive ingredients • 1 U.S. Patent issued covering an extended release opioid dosage form • Impede® Technology patents pending • Additional

  26. Slide 26: Financial and Share Summary @ 12/31/2013

    26 Selected Financial Information $ Millions Cash, Cash Equivalents and Marketable Securities $26.1 Debt (60 month term @ 8.35% with interest only thru March, 2015 and principal & interest to December 2018) $10.0 Shares Outstanding Millions Total Common Shares Outstanding 48.848 Shares Held by 2 Lar

  27. Slide 27: Acura Pharmaceuticals, Inc.

    Acura Pharmaceuticals, Inc. 616 N. North Court, Suite 120 Palatine, IL 60067 (847) 705 - 7709 NASDAQ: ACUR www.AcuraPharm.com Copyright © 2012 Acura Pharmaceuticals. All rights reserved.

Acura Pharmaceuticals — Roth Capital Conference March 2014 on 6ix